B细胞淋巴瘤中的循环肿瘤DNA:技术进展、临床应用及转化研究展望
本文综述了B细胞淋巴瘤中循环肿瘤DNA(ctDNA)检测与基因分型技术的综合分析前与分析技术要求、各类方法的优势与局限,并探讨ctDNA在淋巴瘤亚型分类、治疗反应评估、结局预测及可测量残留病监测中的潜在应用,以及作为前瞻性临床试验替代终点和决策工具的前景。
要点
- ctDNA可捕获肿瘤全部突变谱,较常规组织活检通常仅针对单一肿瘤部位具有决定性优势。
- 连续重复ctDNA检测可实时反映肿瘤遗传组成并量化肿瘤负荷。
- ctDNA有望用于淋巴瘤亚型分类、治疗反应评估、结局预测及可测量残留病监测。
核心结论
- ctDNA分析已成为B细胞淋巴瘤患者管理的潜在新策略,可实现无创疾病监测和风险分层。
- ctDNA有望作为新型替代终点纳入前瞻性临床试验,并作为决策工具指导未来淋巴瘤治疗。
研究设计与样本
- 综述,总结了B细胞淋巴瘤中ctDNA检测与基因分型的技术,聚焦分析前与分析技术要求、各类方法的优势与局限,并广泛综述ctDNA在临床实践和转化研究中的潜在应用。
主要发现
- ctDNA评估可捕获肿瘤全部突变谱,而常规组织活检通常仅针对单一肿瘤部位。
- 由于无创或微创特性,连续重复ctDNA分析可实时反映遗传组成并便于在疾病任何阶段量化肿瘤负荷。
- 综述描述了ctDNA如何可能增强淋巴瘤亚型分类、治疗反应评估、结局预测和可测量残留病监测。
临床怎么用
- 作者认为ctDNA可作为新型替代终点纳入前瞻性临床试验,并作为决策工具指导未来淋巴瘤治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA) profiling has become a potential novel strategy for patient management in B-cell lymphoma. Emerging innovative therapeutic options and an unprecedented growth in our understanding of biological and molecular factors underlying lymphoma heterogeneity have fundamentally increased the need for precision-based tools facilitating personalized and accurate disease profiling and quantification. By capturing the entire mutational landscape of tumors, ctDNA assessment has some decisive advantages over conventional tissue biopsies, which usually target only one single tumor site. Due to its non- or minimal-invasive nature, serial and repeated ctDNA profiling provides a real-time picture of the genetic composition and facilitates quantification of tumor burden any time during the course of the disease. In this review, we present a comprehensive overview of technologies used for ctDNA detection and genotyping in B-cell lymphoma, focusing on pre-analytical and technical requirements, the advantages and limitations of various approaches, and highlight recent advances around improving sensitivity and suppressing technical errors. We broadly review potential applications of ctDNA in clinical practice and for translational research by describing how ctDNA might enhance lymphoma subtype classification, treatment response assessment, outcome prediction, and monitoring of measurable residual disease. We finally discuss how ctDNA could be implemented in prospective clinical trials as a novel surrogate endpoint and be utilized as a decision-making tool to guide lymphoma treatment in the future.
引用
- Lauer EM, Mutter J, Scherer F, et al. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. Leukemia. 2022. PMID: 35701522. doi:10.1038/s41375-022-01618-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。